Terns Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Good morning. I'm Eric Joseph, Senior Biotech Analyst at J.P. Morgan. Our next presenting company is Terns Pharmaceuticals. And presenting on behalf of the company is President and Head of R&D, Erin Quirk (Conference Instructions). So with that, Erin, please.
Thanks very much, Eric. And thanks to you and the entire J.P. Morgan team for the opportunity to provide you with an overview of the company, Terns Pharmaceuticals, and how we are working hard to address unmet needs for serious diseases. As always, I invite you to review our forward-looking statements on Terns' website.
And then, just a snapshot. Terns is developing small molecules with clinically validated mechanisms of action to address key high [unmet] areas of need serious diseases such as oncology and metabolic diseases. We are working on three internally discovered, clinically validated mechanisms, which highlight our pipeline in three indications with large
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
